A Randomized, Controlled, Open-label, Multicenter, Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Chlorogenic Acid for Injection in the Treatment of Recurrent Grade IV Glioblastoma (GBM) was performed at Chongqing Cancer Hospital and Harbin Medical University Cancer Hospital respectively on 25 April 2019 and 7 May 2019 and openly recruited patients with recurrence glioblastoma who are eligible for enrollment.